Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Proia

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Nature Protocols|April 5, 2007
Reconstruction of human mammary tissues in a mouse modelDavid A Proia, Charlotte Kuperwasser
Cell Cycle (Georgetown, Tex.)|August 6, 2005
Stroma: tumor agonist or antagonistDavid A Proia, Charlotte Kuperwasser
Cancer Research|February 22, 2014
Ganetespib and HSP90: translating preclinical hypotheses into clinical promiseDavid A Proia, Richard C Bates
Cancer Immunology Research|May 8, 2015
Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer TherapyDavid A Proia, Gunnar F Kaufmann
The Journal of Biological Chemistry|December 15, 2005
Dual roles for the phosphatase PPM1D in regulating progesterone receptor functionDavid A Proia, Bonnie W Nannenga, Lawrence A Donehower, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 10, 2014
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer modelsLuke Whitesell, Sandro Santagata, Marc L Mendillo, et al.
Investigational New Drugs|April 1, 2014
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancerSuqin He, Donald L Smith, Manuel Sequeira, et al.
Oncotarget|October 31, 2015
Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibitionRoberto Gomez-Casal, Michael W Epperly, Hong Wang, et al.
Investigational New Drugs|May 21, 2013
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypesJulie C Friedland, Donald L Smith, Jim Sang, et al.
Molecular Cancer Research : MCR|February 21, 2014
mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesisJaime Acquaviva, Suqin He, Jim Sang, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Nature Protocols|April 5, 2007
Reconstruction of human mammary tissues in a mouse modelDavid A Proia, Charlotte Kuperwasser
Cell Cycle (Georgetown, Tex.)|August 6, 2005
Stroma: tumor agonist or antagonistDavid A Proia, Charlotte Kuperwasser
Cancer Research|February 22, 2014
Ganetespib and HSP90: translating preclinical hypotheses into clinical promiseDavid A Proia, Richard C Bates
Cancer Immunology Research|May 8, 2015
Targeting Heat-Shock Protein 90 (HSP90) as a Complementary Strategy to Immune Checkpoint Blockade for Cancer TherapyDavid A Proia, Gunnar F Kaufmann
The Journal of Biological Chemistry|December 15, 2005
Dual roles for the phosphatase PPM1D in regulating progesterone receptor functionDavid A Proia, Bonnie W Nannenga, Lawrence A Donehower, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 10, 2014
HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer modelsLuke Whitesell, Sandro Santagata, Marc L Mendillo, et al.
Investigational New Drugs|April 1, 2014
The HSP90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancerSuqin He, Donald L Smith, Manuel Sequeira, et al.
Oncotarget|October 31, 2015
Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to HSP90 inhibitionRoberto Gomez-Casal, Michael W Epperly, Hong Wang, et al.
Investigational New Drugs|May 21, 2013
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypesJulie C Friedland, Donald L Smith, Jim Sang, et al.
Molecular Cancer Research : MCR|February 21, 2014
mTOR inhibition potentiates HSP90 inhibitor activity via cessation of HSP synthesisJaime Acquaviva, Suqin He, Jim Sang, et al.
Pageof 5